Urocitra

  • #
    medicine name: Urocitra
  • #
    Generic name: Potassium citrate
  • #
    Medication Shape: Oral tablets
  • #
    Packing: Bottle of 90 tablets
  • #
    Pharmaceutical group: Kidneys and urinary tract

Indications:

For the management of renal tubular acidosis (RTA) with calcium nephrolithiasis
Hypocitraturic calcium oxalate nephrolithiasis of any etiology
Uric acid nephrolithiasis (with or without calcium stones)

Method of Use:

Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0.
Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack.
Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times -per day with meals or within 30 minutes after meals or bedtime snack.                                                                                                                     

prohibited usage:

Hypersensitivity to potassium citrate or any other ingredient.
Patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia). Such conditions include chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown
Patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture.
Patients with peptic ulcer disease.
Patients with active urinary tract infection.
Patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min).